奥氮平与利培酮对老年期分裂症患者体重影响的对照研究

Comparative study of olanzapine and risperidone on body weight in elderly schizophrenia.

目的探讨奥氮平与利培酮治疗老年期首发精神分裂症时对体重、影响及其差别。方法对51例符合CCMD-3诊断标准的老年首发分裂症患者，分为奥氮平组（n=26）及利培酮组（n=25）进行治疗，于治疗前及治疗后第二，四，六及八周末分别测查体重、体重指数。结果两组指标均从第四周末后明显升高，服药八周后，奥氮平组体重、体重指数平均增加5．17kg、2．05kg／m^2，利培酮组增加3．86kg、1．45kg^2／m^2，且奥氮平组的体重增加值明显大于利培酮组；体重增加入数共27人，占总人数的52，94％，其中奥氮平组18例，利培酮组9例；与治疗前比较．奥氮平组的肥胖和超体重指数人数明显增多。以上差别均有显著性意义（P〈0．05～0．01）。结论奥氮平与利培酮均能引起体重、体重指数增加。且奥氮平组更明显．应予以重视。

OBJECTIVE To analyze the influences of olanzapine and risperidone on the body weight , BMI in the treatment of elderly first - episode schizophrenia. METHODS 51 patients with schizophrenia by CCMD - 3 were randomly allocated to two groups which treated with olanzapine or risperidone for 8 weeks. Body weight,BMI were measured before and at the ends of 2,4,8 weeks of treatment. RESULTS Both the two groups gained marked weight increment in olanzapine group was more marked ;There were 27 patients of weight gain （52.94% of all）, 18 in olanzapine group and 9 in another;Comparing to the origin, obviously increasing persons of heavyweight and obesity were added to olanzapine group after 8weeks treatment . All reults these showed significantly statistical difference （P 〈0. 05-0. 01 ）. CONCLUSIONS Olanzapine and risperidone all cause elevations in weight, and olanzapine leads to gain these more obviously. More attention should be paid to this.